{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T21:58:57Z","timestamp":1700863137245},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The SARS-CoV-2 pandemic has disrupted clinical trials worldwide. The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) has tracked clinical trial disruption by surveying its 58 trial sites across 17 European countries and collated information on measures to mitigate the impact of the pandemic and ensure trial continuity. Here, we present recommendations on how to reduce the risk of SARS-CoV-2 exposure to patients and trial staff by implementing remote trial visits where possible, using home assessments, video and phone calls, electronic consent, and home delivery of study drugs. We discuss the practicalities of remote source data verification, protocol amendments, changing trial site location, and staff absences and home working. We outline recommendations on how to protect trial outcomes, including home assessments, safety reporting, protocol deviations, and recruitment challenges. Finally, we discuss the importance of continued access to study drugs via extension trials for some patients. This guidance was co-created from the shared knowledge and experience of sites in our network and was re-distributed directly to all ECFS-CTN sites to help mitigate the impact of further waves of the SARS-CoV-2 pandemic. We will also use this guidance to assist companies, academia, and consortia with future protocol design and risk mitigation plans. This guidance can be applied to clinical trials in other diseases and could help sites that are not supported by clinical trial networks.<\/jats:p>","DOI":"10.1186\/s13063-021-05457-5","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T20:02:35Z","timestamp":1630180955000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures"],"prefix":"10.1186","volume":"22","author":[{"given":"Silke","family":"van Koningsbruggen-Rietschel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Dunlevy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Bulteel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Verbrugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hettie M.","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Dufeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieven J.","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian G.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"issue":"3","key":"5457_CR1","doi-asserted-by":"publisher","first-page":"2002114","DOI":"10.1183\/13993003.02114-2020","volume":"56","author":"S van Koningsbruggen-Rietschel","year":"2020","unstructured":"van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, Downey DG, Dupont L. SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network. Eur Respir J. 2020;56(3):2002114. https:\/\/doi.org\/10.1183\/13993003.02114-2020.","journal-title":"Eur Respir J."},{"issue":"1","key":"5457_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13063-021-05219-3","volume":"22","author":"JM Unger","year":"2021","unstructured":"Unger JM, Xiao H. The COVID-19 pandemic and new clinical trial activations. Trials. 2021;22(1):260. https:\/\/doi.org\/10.1186\/s13063-021-05219-3.","journal-title":"Trials."},{"issue":"3","key":"5457_CR3","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3126\/nje.v10i3.31622","volume":"10","author":"B Sathian","year":"2020","unstructured":"Sathian B, Asim M, Banerjee I, Pizarro AB, Roy B, van Teijlingen ER, et al. Impact of COVID-19 on clinical trials and clinical research: a systematic review. Nepal J Epidemiol. 2020;10(3):878\u201387. https:\/\/doi.org\/10.3126\/nje.v10i3.31622.","journal-title":"Nepal J Epidemiol."},{"key":"5457_CR4","unstructured":"Food and Drug Administration. FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic.2020 [updated May 14 2020]. Available from: https:\/\/www.fda.gov\/media\/136238\/download. Accessed 12 Aug 2021."},{"key":"5457_CR5","unstructured":"European Medicines Agency. Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic.2020 [updated April 28 2020]. Available from: https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-10\/guidanceclinicaltrials_covid19_en.pdf. Accessed 12 Aug 2021."},{"issue":"6","key":"5457_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00431-016-2712-z","volume":"175","author":"K De Boeck","year":"2016","unstructured":"De Boeck K, Bulteel V, Fajac I. Disease-specific clinical trials networks: the example of cystic fibrosis. Eur J Pediatr. 2016;175(6):817\u201324. https:\/\/doi.org\/10.1007\/s00431-016-2712-z.","journal-title":"Eur J Pediatr."},{"key":"5457_CR7","doi-asserted-by":"publisher","unstructured":"Naerlich, et al. Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. J CystFibros. 2021;S1569-1993(21)00099-0. https:\/\/doi.org\/10.1016\/j.jcf.2021.03.017.","DOI":"10.1016\/j.jcf.2021.03.017"},{"key":"5457_CR8","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S1569-1993(21)01089-4","volume":"20","author":"S Van Koningsbruggen-Rietschel","year":"2021","unstructured":"Van Koningsbruggen-Rietschel S, Bulteel V, Dunlevy F, Hayes K, Verbrugge A, Downey D. P062 impact of the SARS-CoV-2 pandemic on clinical trials in the ECFS-CTN during 2020. J Cyst Fibros. 2021;20:S57. https:\/\/doi.org\/10.1016\/S1569-1993(21)01089-4.","journal-title":"J Cyst Fibros."},{"key":"5457_CR9","unstructured":"Critical Appraisal Skills Programme. CASP Qualitative Checklist 2018 [Available from: https:\/\/casp-uk.b-cdn.net\/wpcontent\/uploads\/2018\/03\/CASP-Qualitative-Checklist-2018_fillable_form.pdf]. Accessed 12 Aug 2021."},{"issue":"9280","key":"5457_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0140-6736(01)05627-6","volume":"358","author":"K Malterud","year":"2001","unstructured":"Malterud K. Qualitative research: standards, challenges, and guidelines. Lancet. 2001;358(9280):483\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(01)05627-6.","journal-title":"Lancet."},{"issue":"aug07 3","key":"5457_CR11","doi-asserted-by":"publisher","first-page":"a1035","DOI":"10.1136\/bmj.a1035","volume":"337","author":"A Kuper","year":"2008","unstructured":"Kuper A, Lingard L, Levinson W. Critically appraising qualitative research. BMJ. 2008;337(aug07 3):a1035. https:\/\/doi.org\/10.1136\/bmj.a1035.","journal-title":"BMJ."},{"key":"5457_CR12","unstructured":"Paynter A, Goss C, Heltshe S, Khan U, Lechtzin N, Mayer-Hamblett N, editors. Home versus clinic spirometry to informtrial endpoints in CF: EICE experience (abstract and poster). North American Cystic Fibrosis Conference; 2020; Online."},{"key":"5457_CR13","unstructured":"(EMA) EMA. Kaftrio 2021 [updated 25 May 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio. Accessed 12 Aug 2021."},{"issue":"1","key":"5457_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13063-021-05200-0","volume":"22","author":"L Robison","year":"2021","unstructured":"Robison L, Cho Y, Viecelli AK, Johnson DW, Hawley CM, Valks A, et al. Conducting clinical trials during the COVID-19 pandemic\u2014a collaborative trial network response. Trials. 2021;22(1):278. https:\/\/doi.org\/10.1186\/s13063-021-05200-0.","journal-title":"Trials."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05457-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05457-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05457-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T20:09:09Z","timestamp":1630181349000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05457-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5457"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05457-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FD, VB, KH, AV, SvK, and LD declare that they have no competing interests.HJ has received a speaker\u2019s fee and a research grant for an investigator-initiated study from Vertex.NJS has received fees for consultancy and speaking from Vertex, Chiesi, Gilead, Roche, Teva, Zambon, and Pulmocide.DD has received honoraria from Vertex and Chiesi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"578"}}